Cargando…
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
Multiple myeloma is an incurable malignant plasma cell-originating cancer. Although its treatment outcomes have improved with the use of glucocorticoids, alkylating drugs, and novel agents, including proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalido...
Autores principales: | Lee, Ho Sup, Min, Chang-Ki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016292/ https://www.ncbi.nlm.nih.gov/pubmed/27604793 http://dx.doi.org/10.3904/kjim.2016.110 |
Ejemplares similares
-
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
por: Zhang, Shijia, et al.
Publicado: (2020) -
Lenalidomide in the Treatment of Young Patients with Multiple Myeloma: From Induction to Consolidation/Maintenance Therapy
por: Lupo, Barbara, et al.
Publicado: (2012) -
Maintenance therapy in multiple myeloma
por: Harousseau, Jean-Luc
Publicado: (2009) -
The role of maintenance therapy in multiple myeloma
por: Lipe, B, et al.
Publicado: (2016) -
Consolidation in multiple myeloma – current status and perspectives
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2014)